Just two months ago, AbbVie’s Mavyret joined the ranks of treatments approved by the FDA for chronic infection of the hepatitis C virus (HCV). Hepatitis C continues to be a major public health issue, affecting nearly 4 million Americans. It’s a good time to review best practices with this newest HCV medication.
The American Association for the Study of Liver Diseases (AASLD) points out that Mavyret is a first-line treatment option for all genotypes of HCV. Mavyret can be prescribed to patients with all genotypes of HCV, even to those with mild cirrhosis. Adding to its versatility, it can also be used in genotyple 1 patients who failed certain previous treatments. For treatment naïve patients (without cirrhosis), Mavyret can cure HCV in just eight weeks.
Mavyret is actually a one-pill combination of two direct-acting antivirals: glecaprevir and pibrentasvir. Patients are prescribed cartons of the pills and it is administered as three tablets taken once daily, with food. Most people take the medication daily for eight weeks, although treatment-naïve patients who also have compensated cirrhosis will be treated for 12 weeks and certain treatment-experienced patients could need 16 weeks. This medication should not be used in patients with moderate (Child-Pugh B) or severe hepatic impairment (Child-Pugh C).
Nine different clinical trials – including 2,300 patients and covering all six genotypes – have demonstrated the efficacy and safety of Mavyret. The sustained viral response in these studies ranged from 92-100%, even for the eight-week treatment length. Safety concerns are few, with the most common problems reported as headaches and fatigue. However, patients on Mavyret cannot also take rifampin, atazanavir, atorvastatin, lovastatin, or simvastatin.
Finally, a key benefit with Mavyret is the more modest price point, with it being the least costly HCV medication on the market.
BioPlus Specialty Pharmacy has available the HCV Treatment Path app, which offers prescribers guidelines and tools to streamline the selection of the hepatitis C treatment that is best-suited to individual patients, based on criteria from experts such as the FDA and the AASLD (American Association for the Study of Liver Diseases). The treatment landscape for this disease is under continual change and this app keeps the latest information easily accessible.
Learn more about the HCV Treatment Path App.
AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. hcvguidelines.org.